All patient identifiable information has been removed to maintain patient privacy. The facts of this case are based on actual medical cases, but the case and information provided are offered solely for educational purposes. The information presented is not offered as, nor does it represent, consultation or second opinion.
IHC ATLAS
Browse through whole slide images (WSIs) in the IHC image gallery, containing clinical cases, provided and consensus scored by the Pathology Faculty. Contribute to the community polling with the What’s your interpretation? tool for featured clinical cases.
Members of the Breast Pathology Faculty have been contracted as paid advisors through Daiichi Sankyo and AstraZeneca, and have received compensation for their time.
EXPLORE CLINICAL CASES
IHC image gallery
Explore the collection of hand-selected clinical cases, organized within categories. Click on each thumbnail to enlarge the image and select View whole slide image to inspect the WSI in detail.
- Challenging staining patterns
- Non-specific staining patterns/artifacts
- Non-consensus scored clinical cases
- Non-challenging staining patterns
PRACTICE SCORING
What's your interpretation?
Click through the image carousel, view the WSIs, and select your HER2 IHC score. Submit to see how your score compared to others or simply ‘reveal poll’.
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Dr. Michael Feldman
Vice Chair of Clinical Services, Pathology and Laboratory Medicine, Hospital of the University of PennsylvaniaInvasive breast carcinoma
Mobile View Text
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; IPLC, invasive pleomorphic lobular carcinoma; NST, non-special type; WSI, whole slide image.
©2023 Daiichi Sankyo, Inc. and AstraZeneca
US-77216, PP-US-8201a-1686 10/23
Request an AstraZeneca Medical Affairs Representative Follow-Up